These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33804911)

  • 1. The PI3Kδ Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential.
    Barrachina MN; Izquierdo I; Hermida-Nogueira L; Morán LA; Pérez A; Arroyo AB; García-Barberá N; González-Conejero R; Troitiño S; Eble JA; Rivera J; Martínez C; Loza MI; Domínguez E; García Á
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33804911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
    Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
    Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
    [No Abstract]   [Full Text] [Related]  

  • 3. The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function.
    Chellappa S; Kushekhar K; Munthe LA; Tjønnfjord GE; Aandahl EM; Okkenhaug K; Taskén K
    J Immunol; 2019 Mar; 202(5):1397-1405. PubMed ID: 30692213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.
    Palazzo A; Herter S; Grosmaire L; Jones R; Frey CR; Limani F; Bacac M; Umana P; Oldham RJ; Marshall MJE; Cox KL; Turaj AH; Cragg MS; Klein C; Carter MJ; Tannheimer S
    J Immunol; 2018 Apr; 200(7):2304-2312. PubMed ID: 29453281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist.
    Mousa SA; Bozarth JM; Forsythe MS; Jackson SM; Leamy A; Diemer MM; Kapil RP; Knabb RM; Mayo MC; Pierce SK
    Circulation; 1994 Jan; 89(1):3-12. PubMed ID: 8281661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory Effect of Idelalisib, a Selective Phosphatidylinositol 3-Kinase δ Inhibitor, on Adipogenesis in an In Vitro Model of Graves' Orbitopathy.
    Ko J; Kim JY; Lee EJ; Yoon JS
    Invest Ophthalmol Vis Sci; 2018 Sep; 59(11):4477-4485. PubMed ID: 30193323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual inhibition of PI3K and mTOR by VS-5584 suppresses thrombus formation.
    Später T; Müller I; Eichler H; Menger MD; Laschke MW; Ampofo E
    Platelets; 2018 May; 29(3):277-287. PubMed ID: 28503993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idelalisib.
    Zirlik K; Veelken H
    Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GSK669, a NOD2 receptor antagonist, inhibits thrombosis and oxidative stress via targeting platelet GPVI.
    Pan G; Chang L; Zhang J; Liu Y; Hu L; Zhang S; Zhang J; Qiao J; Jakopin Ž; Hu H; Dong J; Ding Z
    Biochem Pharmacol; 2021 Jan; 183():114315. PubMed ID: 33152345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of WO2014075392 and WO2014075393, Merck's first PI3Kδ inhibitor filings.
    Norman P
    Expert Opin Ther Pat; 2014 Nov; 24(11):1277-82. PubMed ID: 25326077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idelalisib inhibits osteoclast differentiation and pre-osteoclast migration by blocking the PI3Kδ-Akt-c-Fos/NFATc1 signaling cascade.
    Yeon JT; Kim KJ; Son YJ; Park SJ; Kim SH
    Arch Pharm Res; 2019 Aug; 42(8):712-721. PubMed ID: 31161369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3Kδ Is a Therapeutic Target in Hepatocellular Carcinoma.
    Ko E; Seo HW; Jung ES; Ju S; Kim BH; Cho H; Kim YJ; Park YM; Kim JS; Jung G
    Hepatology; 2018 Dec; 68(6):2285-2300. PubMed ID: 30300952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in
    Dornan GL; Siempelkamp BD; Jenkins ML; Vadas O; Lucas CL; Burke JE
    Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1982-1987. PubMed ID: 28167755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of novel purinyl quinazolinone derivatives as PI3Kδ-specific inhibitors for the treatment of hematologic malignancies.
    Kim YS; Cheon MG; Boggu PR; Koh SY; Park GM; Kim G; Park SH; Park SL; Lee CW; Kim JW; Jung YH
    Bioorg Med Chem; 2021 Sep; 45():116312. PubMed ID: 34332211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase 1 study of the phosphatidylinositol 3-kinase δ inhibitor idelalisib in patients with allergic rhinitis.
    Horak F; Puri KD; Steiner BH; Holes L; Xing G; Zieglmayer P; Zieglmayer R; Lemell P; Yu A
    J Allergy Clin Immunol; 2016 Jun; 137(6):1733-1741. PubMed ID: 26915677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
    Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
    Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
    Lampson BL; Brown JR
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WY-14643, a novel antiplatelet and antithrombotic agent targeting the GPIbα receptor.
    Cao C; Yang Q; Xia X; Chen Z; Liu P; Wu X; Hu H; Ding Z; Li X
    Thromb Res; 2024 Jun; 238():41-51. PubMed ID: 38669962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
    Greenwell IB; Flowers CR; Blum KA; Cohen JB
    Expert Rev Anticancer Ther; 2017 Mar; 17(3):271-279. PubMed ID: 28112970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3K isoform-selective inhibitors: next-generation targeted cancer therapies.
    Wang X; Ding J; Meng LH
    Acta Pharmacol Sin; 2015 Oct; 36(10):1170-6. PubMed ID: 26364801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.